Methylation status of NEUROG2 and NID2 improves the diagnosis of stage I NSCLC

Geng,Junfeng; Sun,Jinfeng; Lin,Qiang; Gu,Jun; Zhao,Yangxing; Zhang,Hongyu; Feng,Xu; He,Yinghua; Wang,Wei; Zhou,Xiaoyu; Yu,Jian

doi:10.3892/ol.2012.587

Methylation status of NEUROG2 and NID2 improves the diagnosis of stage I NSCLC

Authors:
- Junfeng Geng
- Jinfeng Sun
- Qiang Lin
- Jun Gu
- Yangxing Zhao
- Hongyu Zhang
- Xu Feng
- Yinghua He
- Wei Wang
- Xiaoyu Zhou
- Jian Yu
View Affiliations

Affiliations: Department of General Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, P.R. China, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, P.R. China, Department of General Thoracic Surgery, Guangxi Medical University, Tumor Hospital, Nanning 530022, P.R. China, Key Laboratory of Contraceptive Drugs and Devices, National Population and Family Planning Commission, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China
Published online on: February 1, 2012 https://doi.org/10.3892/ol.2012.587
Pages: 901-906

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In our previous study, we attempted to develop a tool for the early diagnosis of non-small cell lung cancer (NSCLC) using DNA methylation biomarkers. With the aim of improving the diagnostic potential by optimizing the composition of the target set, in this study, 13 candidate genes (ACTA1, AIDH1A2, CBX8, CDH8, EVX1, MGC16275, NEUROG1, NEUROG2, NID2, OTX2OS1, PGAM2, PHOX2B and TOX) were analyzed by methylation-specific PCR to determine the methylation status of each gene in 5 NSCLC cell lines and in lung tissue samples from 15 healthy volunteers, 103 stage I NSCLC patients and 26 non-cancerous control patients. Results showed that NEUROG2 and NID2 were hypermethylated in stage I NSCLC tissues (31.07 and 46.60%, respectively) and unmethylated in normal lung tissues (0/15) and non-cancerous tissues (0/26). Following recombination, an optimized 5-gene panel (NEUROG2, NID2, RASSF1A, APC and HOXC9) achieved a sensitivity of 91.26% with a specificity of 84.62% in the detection of stage I NSCLC. The optimized 5-gene panel greatly improved the diagnostic power for stage I NSCLC.